Answers are grounded in this paper and cite their sources.
Primary coenzyme Q 10 (CoQ 10 ) deficiency encompasses a subset of mitochondrial diseases caused by mutations affecting proteins involved in the CoQ 10 biosynthetic pathway. One of the most frequent clinical syndromes associated with primary CoQ 10 deficiency is the severe infantile multisystemic form, which, until recently, was underdiagnosed. In the last few years, the availability of genetic screening through whole exome sequencing and whole genome sequencing has enabled molecular diagnosis in a growing number of patients with this syndrome and has revealed new disease phenotypes and molecular defects in CoQ 10 biosynthetic pathway genes. Early genetic screening can rapidly and non-invasively diagnose primary CoQ 10 deficiencies. Early diagnosis is particularly important in cases of CoQ 10 deficient steroid-resistant nephrotic syndrome, which frequently improves with treatment. In contrast, the infantile multisystemic forms of CoQ 10 deficiency, particularly when manifesting with encephalopathy, present therapeutic challenges, due to poor responses to CoQ 10 supplementation. Administration of CoQ 10 biosynthetic intermediate compounds is a promising alternative to CoQ 10 ; however, further pre-clinical studies are needed to establish their safety and efficacy, as well as to elucidate the mechanism of actions of the intermediates. Here, we review the molecular defects causes of the multisystemic infantile phenotype of primary CoQ 10 deficiency, genotype-phenotype correlations, and recent therapeutic advances.
No takes yet. Share an insight, caveat, or question.
Berardo et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: